EMR posts modest Q2 growth as pricing and demand offset geopolitical headwinds, while backlog strength and orders signal momentum into a stronger second half.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
EMR posts modest Q2 growth as pricing and demand offset geopolitical headwinds, while backlog strength and orders signal momentum into a stronger second half.
Engineering and automation solutions company Emerson (NYSE:EMR) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.9% year on year to $4.56 billion. On the other hand, the company expects next quarter’s revenue to be around $4.80 billion, close to analysts’ estimates. Its non-GAAP profit of $1.54 per share was in line with analysts’ consensus estimates.